Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 7,579 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Clear all
Completed Not applicable Interventional

Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

NCT01071226
View directory record Official record
Conditions
Malignant Diseases (ie, Leukemia, MDS, Lymphoma), Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)
Interventions
CliniMACS (CD+3, CD+19 depletion), CliniMACS (CD 34+ positive selection), HSCT
Device · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 22 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 20, 2026, 10:05 PM EDT
Completed No phase listed Observational

Low Dose CT Distal Radius Fractures

NCT03423043
View directory record Official record
Conditions
Radius Fractures
Interventions
Low Dose CT Scan of the Wrist
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 20, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Results available

Safety Study of Femoral Neck Fracture System

NCT03721835
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
CONQUEST FN Femoral Neck Fracture System
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Macon, Georgia • Winston-Salem, North Carolina • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT01038635
View directory record Official record
Conditions
Leukemia
Interventions
5-Azacytidine, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 20, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Osteogenesis Imperfecta Blood Pressure Study

NCT04169568
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Manual cuff blood pressure
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
1 Year to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 20, 2026, 10:05 PM EDT
Recruiting No phase listed Observational

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

NCT07203768
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
Not listed
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years to 100 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms

NCT00076050
View directory record Official record
Conditions
Menopause, Osteoporosis, Osteopenia
Interventions
Soy isoflavones, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
248 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

NCT02699697
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone, Pain
Interventions
External Beam Radiation Therapy, Palliative Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

NCT04081220
View directory record Official record
Conditions
Thrombocythemia, Essential
Interventions
IMG-7289
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 20, 2026, 10:05 PM EDT
Completed No phase listed Observational

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

NCT00837746
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

NCT01440803
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Teriparatide, Saline Placebo
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

NCT04761770
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Interventions
Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells
Other · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting No phase listed Observational

Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up

NCT07245810
View directory record Official record
Conditions
Mandibular Fractures, Facial Fracture, Maxilla Fracture, Orthognathic Surgical Procedures
Interventions
Orthognatic surgery, Reconstructive maxillofacial surgery, Mandible and maxillofacial trauma surgery
Device
Lead sponsor
Stryker Craniomaxillofacial
Industry
Eligibility
Not listed
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

NCT02574286
View directory record Official record
Conditions
Gaucher Disease
Interventions
Velaglucerase alfa, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Stimulation of Growth in Children With Short Stature

NCT04226586
View directory record Official record
Conditions
Nutritional Stunting, Growth Failure
Interventions
Essential Amino Acid (EAA) group, Placebo
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 20, 2026, 10:05 PM EDT
Not listed Not applicable Interventional

SPIRA™-A 3D and HCT/p DBM vs. Medtronic Divergent™-L/Perimeter™ and Recombinant BMP-2

NCT04566874
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis, Scoliosis
Interventions
ALIF
Device
Lead sponsor
Camber Spine Technologies
Industry
Eligibility
22 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

OptiMesh® for Lumbar Interbody Fusion Trial (OLIF)

NCT00764491
View directory record Official record
Conditions
Degeneration of Lumbar Intervertebral Disc
Interventions
Structural Allograft Spacer, OptiMesh 1500S
Device
Lead sponsor
Spineology, Inc
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Coeur d'Alene, Idaho • Aurora, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 20, 2026, 10:05 PM EDT
Not yet recruiting Not applicable Interventional

Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries

NCT07828613
View directory record Official record
Conditions
Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower
Interventions
Accelerated Flap Coverage Surgery, Standard of Care Flap Timing
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
31
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003960
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 20, 2026, 10:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Demineralized Bone Matrix Rotator Cuff Study

NCT04686396
View directory record Official record
Conditions
Rotator Cuff Injuries
Interventions
Demineralized bone matrix
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04747613
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02487979
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
149
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 20, 2026, 10:05 PM EDT